Document:

Ex-10.1 Amendment No. 2 to Distribution, Patent &

 

Exhibit 10.1

CONFIDENTIAL
MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

AMENDMENT NO. 2 TO DISTRIBUTION, PATENT & TRADEMARK LICENSE,

MARKETING AND SUPPLY AGREEMENT

     This Amendment Agreement (this “Amendment No. 2”) is entered into as of the 18th day of August
2006, by and between Kos Pharmaceuticals, Inc., a Florida corporation (“Kos”), and Merck KGaA, an
entity organized under German law and registered in the commercial registry of the local court of
Darmstadt under HRB 6164 (“Merck”).

Recitals

     A. Kos and Merck are parties to that certain Distribution, Patent & Trademark License,
Marketing and Supply Agreement entered into as of October 23, 2002, as amended (the “Agreement”).

     B. The Agreement provides for certain rights and obligations with respect to two Kos
products: Niaspan® and Advicor®.

     C. Due to changed circumstances and other mutual considerations, the Parties desire to amend
the Agreement to remove Advicor from the Agreement in all respects, while leaving the Agreement in
place solely with respect to Niaspan.

     D. Except as otherwise stated herein, terms defined in the Agreement shall have the same
meanings when used herein. Unless otherwise stated, references to Sections herein are to Sections
in the Agreement and references to Appendices are to Appendices to the Agreement.

Amendment Agreement

     The Parties hereby agree that henceforth any and all references contained in the Agreement
shall hereby be modified or revised as follows:

     1. The term “Product(s)” shall mean Niaspan and shall not mean or include Advicor or any other
product. Where the phrases “both Products” or “Niaspan or Advicor” or “Niaspan and Advicor” or
similar phrases are used, these shall be understood to be references to Niaspan only.

     2. Clause (ii) is deleted from Section 1.22 (definition of “Initial Indications”).

     3. “ or, as applicable, **** of Advicor” is stricken from the first sentence of Section 1.27
(definition of “Minimum Transfer Price”).

     4. The term “New Products” shall mean any product or proposed product, other than the Products
and Product Improvements or Kos’ Niaspan/simvastatin combination products (it being understood and
agreed that notwithstanding the foregoing, Kos shall not enter into an arrangement with any
Third-Party for the development or commercialization of a Niaspan/simvastatin combination product
on terms that, when taken as a whole, are materially

 

 

more favorable to such Third-Party, than the terms that Kos has offered to Merck previously),
which contains, in any dosage form and/or formulation ****.

     5. The sentence “Similarly, Advicor will be the ‘Associated Product’ for a Product Improvement
that is associated with Advicor in such manner.” and all following it in Section 1.36 (definition
of “Product Improvements”) are stricken.

     6. Clause (iv) of Section 3.2(b) is stricken.

     7. The following clauses relating to milestones are stricken from the table in Section 5.2,
and in no event shall any such milestone be, or become, payable, whether or not any related event
has occurred prior to (or occurs following) the effectiveness of this Amendment:

	 	 	 
	Marketing Authorization of Advicor for

1st line indication in a Top Market

	 	**** per Top Market ****
	 
	Marketing Authorization of Advicor for

2nd line indication in a Top Market

	 	**** per Top Market ****

Any additional references to Advicor in such table shall also be stricken therefrom.

     8. Section 5.5(b) is stricken.

     9. The parties will, following execution of this Amendment No. 1, attempt to establish
mutually agreeable **** in Section 9.2 due to the fact, that Niaspan will remain the only Product
covered by the Agreement following the removal of Advicor, pursuant hereto. If and when ****, as
contemplated hereunder, are established by the Steering Committee pursuant to Section 9.2, such
**** shall relate solely to **** of Niaspan and shall no longer include any component reflecting
**** of Advicor.

     10. Any reference to Advicor shall be stricken from Section 9.3

     11. Section 11.1(b) is stricken.

     12. The phrase “ and **** for Advicor” is stricken from Section 11.7(f), and the next
following sentence in that Section shall read: “Kos shall inform Merck in writing of any deviation
from the aforementioned **** .”

     13. The phrase “ shall be at least **** for Advicor and” is stricken from Section 11.11.

     14. Section 17.4 is stricken. Accordingly, Merck hereby notifies Kos that no further
reimbursements will become due to Merck under Section 17.4, and agrees to immediately return the
letter of credit specified in Section 5.1 to Kos and to assist Kos, as reasonably requested by Kos,
to immediately terminate the letter of credit referred to in Section 5.1.

-2-

 

     15. The addresses set forth in Section 21 with respect to notices to Kos are updated to be as
follows:

Kos Pharmaceuticals, Inc:

1 Cedar Brook Drive

Cranbury, NJ 08512

Facsimile: (609) 495-0916

Attention: Adrian Adams

President & CEO

-3-

 

	 	 	 
	Copy to:

	 	Andrew I. Koven, Executive Vice President,

General Counsel and Corporate Secretary

1 Cedar Brook Drive

Cranbury, NJ 08512

Facsimile: (609) 495-0916

     16. Appendix A is stricken.

     17. The Indications for Advicor set forth in Appendix B are stricken.

     18. Appendix D shall be stricken in its entirely and replaced with the Appendix D attached
hereto.

     19. The entries with respect to Advicor in bottles and Advicor in blister packs are stricken
from Appendix E.

     20. Except as modified in this Amendment No. 1, the Agreement remains in full force and effect
in accordance with its terms. The provisions of Sections 22 and 23 of the Agreement apply to this
Amendment as if fully set out herein.

[Signature page follows]

-4-

 

NOW THEREFORE, the Parties, through their authorized officers, have executed this Amendment as of
the date first written above.

	 	 	 	 	 
	 	KOS PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ Andrew I. Koven     September 6, 2006
 	 
	 	 	Name:  	Andrew I. Koven 	 
	 	 	Title:  	Executive Vice President,
General
Counsel and Corporate Secretary 	 
	 
	 	MERCK KGaA

 	 
	 	By:  	/s/ Christian Velmer
 	 
	 	 	Name:  	Christian Velmer 	 
	 	 	Title:  	Senior Vice President

Commercial Unit CM Care & Operations 	 
	 
	 	MERCK KGaA

 	 
	 	By:  	/s/ Philipp R. Buehler
 	 
	 	 	Name:  	Philipp R. Buehler 	 
	 	 	Title:  	Legal Counsel

Corporate Legal Department 	 

-5-EX-10.53 Loan and Security Agreement

 

Exhibit 10.53

SECOND AMENDMENT TO AMENDED AND RESTATED

LOAN AND SECURITY AGREEMENT

          THIS SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”)
is made and entered into this 7th day of November, 2006, by and between MASTEC, INC., a
Florida corporation (“MasTec”), the Subsidiaries of MasTec identified on the signature pages hereto
(together with MasTec, hereinafter collectively referred to as the “Borrowers”), the financial
institutions party from time to time to the Loan Agreement (as hereinafter defined) (the “Lenders”)
and BANK OF AMERICA, N.A., a national bank in its capacity as collateral and administrative agent
for the Lenders (together with its successors in such capacity, “Agent”).

Recitals:

          Agent, Lenders and Borrowers are parties to a certain Amended and Restated Loan and Security
Agreement dated May 10, 2005 (as amended, restated, modified or supplemented, and in effect on the
date hereof, the “Loan Agreement”), pursuant to which Agent and Lenders have made certain revolving
credit loans and letter of credit accommodations to or for the benefit of Borrowers.

          MasTec provided to ACE American Insurance Company (“ACE”) certain cash collateral as security
for MasTec’s obligations to ACE under a certain insurance policy issued by ACE for the benefit of
MasTec and the other Borrowers to enable MasTec and Borrowers’ to comply with certain obligations
under worker’s compensation laws and similar legislation. Borrowers now desire to replace the cash
collateral provided to secure MasTec’s obligations to ACE with a Letter of Credit in the stated
amount of $18,000,000 (the amount of the cash collateral currently pledged to ACE) issued pursuant
to the Loan Agreement.

          Borrowers have requested that Agent and Lenders agree that the Letter of Credit to be issued
to ACE will not result in a reduction in Borrowers’ Availability under the Loan Agreement so long
as sufficient cash or other collateral is granted to Agent, for the benefit of itself and Lenders,
for such Letter of Credit.

          In furtherance of the foregoing, Borrowers have requested that Agent and Lenders amend the
Loan Agreement, and Agent and Lenders are willing to do so, on the terms and subject to the
conditions set forth in this Amendment.

          NOW, THEREFORE, for TEN DOLLARS ($10.00) in hand paid and other good and valuable
consideration, the receipt and sufficiency of which are hereby severally acknowledged, the parties
hereto, intending to be legally bound hereby, agree as follows:

          1) Definitions. All capitalized terms used in this Amendment, unless otherwise
defined herein, shall have the meaning ascribed to such terms in the Loan Agreement.

          2) Amendments to Loan Agreement. The Loan Agreement is hereby amended as follows:

               a. By deleting the definition of “Borrowing Base” in its entirety from Section 1.1 of the
Loan Agreement and by inserting the following in lieu thereof:

     Borrowing Base — on any date of determination thereof, an
amount equal to the lesser of: (a) the aggregate amount of the Revolver
Commitments on such date minus the Availability Reserve on such
date, or (b) an amount equal to (i) the sum of the Accounts Formula Amount
on such date plus the Eligible Unbilled Accounts Formula Amount on
such date plus the Fixed Assets Formula Amount on such date
plus the Eligible Cash Collateral Amount on such date minus
(ii) the Availability Reserve on such date. Notwithstanding the foregoing,
in no event shall the aggregate amount of Revolver Loans outstanding at any
date as measured by Eligible Accounts and Eligible Unbilled Accounts of the
Canadian Obligors exceed, in the aggregate, $5,000,000.

               b. By inserting the following new definitions in Section 1.1 of the Loan Agreement in proper
alphabetical sequence:

1

 

     Ace LC — a Letter of Credit issued for the account of MasTec
for the benefit of ACE American Insurance Company (“ACE”) in the stated
amount of $18,000,000 with respect to MasTec’s insurance coverage for claims
under worker’s compensation laws or similar legislation effected through ACE
from time to time.

     Ace LC Collateral Account — a Deposit Account, securities
account or other account established by MasTec at BofA or an Affiliate of
BofA and over which Agent has control within the meaning of the UCC;
provided, that, any interest, interest equivalent or other
income that accrues, from time to time, on the cash or financial assets
maintained or deposited in such account shall be the property of Borrowers
and paid by BofA or its Affiliate to Borrowers from time to time.

     Eligible Cash Collateral — cash and Cash Equivalents of MasTec
that (i) are on deposit in the Ace LC Collateral Account, (ii) are subject
to the perfected, first priority security interest and Lien in favor of
Agent, on behalf of the Secured Parties, upon such cash and Cash
Equivalents, and BofA (or the other applicable depositary institution or
intermediary at which the Ace LC Collateral Account is maintained) has
executed a deposit account control agreement in favor of Agent, for the
benefit of the Secured Parties, or such other documentation as may be
required by Agent with respect to the Ace LC Collateral Account and the cash
and Cash Equivalent maintained therein, in each case in form and substance
satisfactory to Agent in all respects, and (iii) are not subject to any
Lien, claim or other interest in favor of any Person other than Agent.

     Eligible Cash Collateral Amount — on any date of determination,
an amount equal to the lesser of (i) $18,000,000, and (ii) 100% of the
amount of Eligible Cash Collateral on such date; provided,
that, it is the intent of the parties that (i) the amount of
eligible Cash Collateral maintained in the Ace LC Collateral Account shall
be equal to the undrawn amount of the Ace LC on such date, (ii) Borrowers
shall not be required on any date to maintain Eligible Cash Collateral in an
amount greater than the undrawn amount of the Ace LC on such date, and (iii)
to extent that on any date the Eligible Cash Collateral in the Ace LC
Collateral Account exceeds the undrawn amount of the Ace LC on such date,
BofA or its Affiliate at which the Ace LC Collateral Account is maintained
shall, at the request of Borrowers, pay the amount of Eligible Cash
Collateral in excess of undrawn amount of the Ace LC to Borrowers.

               c. By deleting Section 3.2.2 of the Loan Agreement in its entirety and by substituting the
following in lieu thereof:

     3.2.2. LC Facility Fees. Borrowers shall pay: (a)(i) to
Agent, for the Pro Rata account of each Lender for all Letters of Credit,
the Applicable Margin in effect for Revolver Loans that are LIBOR Loans on a
per annum basis based on the average amount available to be drawn under
Letters of Credit outstanding and all Letters of Credit that are paid or
expire during the period of measurement (or, with respect to each Letter of
Credit that is secured by cash deposited by Borrowers into the Cash
Collateral Account on terms satisfactory to Agent, 0.75% (or 0.50% with
respect to the Ace LC) on a per annum basis based on the average amount
available to be drawn under all such cash-collateralized Letters of Credit
outstanding and all such cash-collateralized Letters of Credit that are paid
or expire during the period of measurement) , in each case payable monthly,
in arrears, on the first Business Day of the following month; (ii) to Agent,
for its own account a Letter of Credit fronting fee of 0.125% per annum
based on the average amount available to be drawn under all Letters of
Credit outstanding and all Letters of Credit that are paid or expire during
the period of measurement, payable monthly, in arrears, on the first
Business Day of the following month; and (iii) to Issuing Bank for its own
account all customary charges associated with the issuance, amending,
negotiating, payment, processing and administration of all Letters of
Credit.

               d. By deleting Section 7.1(xi) of the Loan Agreement in its entirety and by substituting the
following in lieu thereof:

     (xi) all monies now or at any time or times hereafter in the possession
or under the control of Agent or a Lender or a bailee or Affiliate of Agent
or a Lender, including any Cash Collateral in the Cash Collateral Account
and cash, Cash Equivalents and other Property in the Ace LC Collateral
Account;

2

 

               e. By deleting Section 7.4.1 of the Loan Agreement in its entirety and by substituting the
following in lieu thereof:

     7.4.1. Cash Collateral. In addition to the items of Property
referred to in Section 7.1 above, (i) the Obligations shall also be secured
by the Cash Collateral (other than any Cash Collateral held in the ACE Cash
Collateral Account) and all of the other items of Property from time to time
described in any of the Security Documents as security for any of the
Obligations, including all of the Collateral described in the Canadian
Security Agreement, in each case to the extent provided herein and (ii) the
LC Obligations relating to the Ace LC, and only such LC Obligation, shall be
secured by all cash, Cash Equivalents and other Property from time to time
in the Ace LC Collateral Account.

          3) Ratification and Reaffirmation. Each Borrower hereby ratifies and reaffirms the
Obligations, each of the Loan Documents and all of such Borrower’s covenants, duties, indebtedness
and liabilities under the Loan Documents.

          4) Acknowledgments and Stipulations. Each Borrower acknowledges and stipulates that
the Loan Agreement and the other Loan Documents executed by such Borrower are legal, valid and
binding obligations of such Borrower that are enforceable against such Borrower in accordance with
the terms thereof; all of the Obligations are owing and payable without defense, offset or
counterclaim (and to the extent there exists any such defense, offset or counterclaim on the date
hereof, the same is hereby waived by such Borrower); the security interests and Liens granted by
such Borrower in favor of Agent are duly perfected, first priority security interests and Liens,
subject only to Permitted Liens; and, as of the close on business on November 6, 2006, the unpaid
principal amount of the Revolver Loans totaled $0, and the face amount of outstanding Letters of
Credit totaled $65,295,498.74.

          5) Representations and Warranties. Each Borrower represents and warrants to Agent and
Lenders, to induce Agent and Lenders to enter into this Amendment, that no Default or Event of
Default exists on the date hereof; the execution, delivery and performance of this Amendment have
been duly authorized by all requisite entity action on the part of such Borrower and this Amendment
has been duly executed and delivered by such Borrower; and all of the representations and
warranties made by Borrowers in the Loan Agreement are true and correct in all material respects on
and as of the date hereof after giving effect to this Amendment and to the revised Schedules to the
Loan Agreement delivered herewith.

          6) Reference to Loan Agreement. Upon the effectiveness of this Amendment, each
reference in the Loan Agreement to “this Agreement,” “hereunder,” or words of like import shall
mean and be a reference to the Loan Agreement, as amended by this Amendment.

          7) Breach of Amendment. This Amendment shall be part of the Loan Agreement and a
breach of any representation, warranty or covenant herein shall constitute an Event of Default.

          8) Conditions Precedent. The amendments contained in Section 2 of this Amendment
shall become effective as of the date hereof, in each case on the date, in each case on the date on
which Agent shall have received, on or before November 7, 2006, the following documents, each of
which shall be satisfactory in form and substance to Agent and in sufficient copies for each
Lender:

     a. this Amendment duly executed and delivered by the Borrowers, the Lenders
and Agent and the Consent and Reaffirmation of Guarantors, duly executed and
delivered by the Guarantors; and

     b. a certificate of the secretary or assistant secretary of each Obligor
having attached thereto the articles or certificate of incorporation and bylaws of
such Obligor (or containing the certification of such secretary or assistant
secretary that no amendment or modification of such articles or certificate of
incorporation or bylaws has become effective since May 10, 2005), and certifying
all entity action, including shareholders’ or members’ approval, if necessary, has
been taken by such Obligor and/or its shareholders or members to authorize the
execution, delivery and performance of this Amendment and the incumbency of the
officers of such Obligor executing this Amendment and any other documents in
connection herewith.

          9) Expenses of Agent. Borrowers agree to pay, on demand, all costs and expenses
incurred by Agent in connection with the preparation, negotiation and execution of this Amendment
and any other Loan Documents executed pursuant hereto and any and all amendments, modifications,
and supplements thereto, including, without limitation, the costs and fees of Agent’s legal counsel
and any taxes or expenses associated with or incurred in connection with any instrument or
agreement referred to herein or contemplated hereby.

3

 

          10) Effectiveness; Governing Law. This Amendment shall be effective upon acceptance
by Agent in Atlanta, Georgia (notice of which acceptance is hereby waived), whereupon the same
shall be governed by and construed in accordance with the internal laws of the State of Georgia.

          11) Successors and Assigns. This Amendment shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and assigns.

          12) No Novation, etc.. Except as otherwise expressly provided in this Amendment,
nothing herein shall be deemed to amend or modify any provision of the Loan Agreement or any of the
other Loan Documents, each of which shall remain in full force and effect. This Amendment is not
intended to be, nor shall it be construed to create, a novation or accord and satisfaction, and the
Loan Agreement as herein modified shall continue in full force and effect.

          13) Counterparts; Telecopied Signatures. This Amendment may be executed in any number
of counterparts and by different parties to this Amendment on separate counterparts, each of which,
when so executed, shall be deemed an original, but all such counterparts shall constitute one and
the same agreement. Any signature delivered by a party by facsimile transmission shall be deemed
to be an original signature hereto.

          14) Further Assurances. Each Borrower agrees to take such further actions as Agent
shall reasonably request from time to time in connection herewith to evidence or give effect to the
amendments set forth herein or any of the transactions contemplated hereby.

          15) Section Titles. Section titles and references used in this Amendment shall be
without substantive meaning or content of any kind whatsoever and are not a part of the agreements
among the parties hereto.

          16) Waiver of Jury Trial. To the fullest extent permitted by Applicable Law, the
parties hereto each hereby waives the right to trial by jury in any action, suit, counterclaim or
proceeding arising out of or related to this Amendment.

[Signatures on following page]

4

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed under seal
and delivered by their respective duly authorized officers on the date first written above.

	 	 	 
	 

	 	BORROWERS:
	 
	 	 
	 

	 	MASTEC, INC.
	 
	 	 
	ATTEST:
	 	 
	/s/ Albert de Cardenas

	 	By: /s/ Stephen M. Wagman
	 

	 	 
	Albert de Cardenas, Secretary

	 	Name: Stephen M. Wagman
	 

	 	Title: Executive Vice President
	[CORPORATE SEAL]
	 	 
	 
	 	 
	 

	 	MASTEC TC, INC.
	 
	 	 
	 

	 	By: /s/ Stephen M. Wagman
	 

	 	 
	 

	 	Name: Stephen M. Wagman
	 

	 	Title: Executive Vice President
	 
	 	 
	 

	 	MASTEC FC, INC.
	 
	 

	 	By: /s/ Stephen M. Wagman
	 

	 	 
	 

	 	Name: Stephen M. Wagman
	 

	 	Title: Executive Vice President
	 
	 	 
	 

	 	MASTEC CONTRACTING COMPANY, INC.
	 
	 

	 	By: /s/ Stephen M. Wagman
	 

	 	 
	 

	 	Name: Stephen M. Wagman
	 

	 	Title: Executive Vice President
	 
	 

	 	MASTEC MINNESOTA SW, LLC
	 
	 

	 	By: /s/ Stephen M. Wagman
	 

	 	 
	 

	 	Name: Stephen M. Wagman
	 

	 	Title: Executive Vice President

[Signatures continue on following page]

5

 

	 	 	 	 	 
	 	MASTEC SERVICES COMPANY, INC.

 	 
	 	By:  	/s/ Stephen M. Wagman
 	 
	 	 	Name:  	Stephen M. Wagman 	 
	 	 	Title:  	Executive Vice President 	 
	 
	 	MASTEC ASSET MANAGEMENT COMPANY, INC.

 	 
	 	By:  	/s/ Stephen M. Wagman
 	 
	 	 	Name:  	Stephen M. Wagman 	 
	 	 	Title:  	Executive Vice President 	 
	 
	 	CHURCH & TOWER, INC.

 	 
	 	By:  	/s/ Stephen M. Wagman
 	 
	 	 	Name:  	Stephen M. Wagman 	 
	 	 	Title:  	Executive Vice President 	 
	 
	 	MASTEC OF TEXAS, INC.

 	 
	 	By:  	/s/ Stephen M. Wagman
 	 
	 	 	Name:  	Stephen M. Wagman 	 
	 	 	Title:  	Executive Vice President 	 
	 
	 	S.S.S. CONSTRUCTION, INC.

 	 
	 	By:  	/s/ Stephen M. Wagman
 	 
	 	 	Name:  	Stephen M. Wagman 	 
	 	 	Title:  	Executive Vice President 	 
	 

[Signatures continue on following page]

6

 

	 	 	 	 	 
	 	AGENT AND LENDERS:

BANK OF AMERICA, N.A., as Agent and a Lender

 	 
	 	By:  	/s/ Dennis S. Losin
 	 
	 	 	Dennis S. Losin, Senior Vice President 	 
	 
	 	LASALLE BUSINESS CREDIT, LLC, as a Lender 	 
	 
	 	 	 
	 	By:  	/s/
             Steven Friedlander
 	 
	 	 	Title:      Senior Vice President 	 
	 	 	 	 
	 
	 	PNC BANK, NATIONAL
ASSOCIATION,
as a Lender 

 	 
	 	By:  	/s/ Alex M. Council
 	 
	 	 	Title: Vice President 	 
	 	 	 	 
	 
	 	GENERAL ELECTRIC CAPITAL CORPORATION,
as a Lender

 	 
	 	By:  	/s/ Mark Kassis
 	 
	 	 	Title: Duly Authorized Signatory 	 
	 	 	 	 

7

 

	 	 	 	 	 

CONSENT AND REAFFIRMATION

          Each of the undersigned guarantors of the Obligations at any time owing to Agent or Lenders
hereby (i) acknowledges receipt of a copy of the foregoing Second Amendment to Amended and Restated
Loan and Security Agreement; (ii) consents to Borrowers’ execution and delivery thereof and of the
other documents, instruments or agreements any Borrower agrees to execute and deliver pursuant
thereto; (iii) agrees to be bound thereby; and (iv) affirms that nothing contained therein shall
modify in any respect whatsoever its respective guaranty of the Obligations and reaffirms that such
guaranty is and shall remain in full force and effect.

          IN WITNESS WHEREOF, the undersigned has executed this Consent and Reaffirmation, as of the
date of such Second Amendment to Amended and Restated Loan and Security Agreement.

	 	 	 	 	 
	 	GUARANTORS:

PHASECOM SYSTEMS, INC.

 	 
	 	By:  	/s/ Stephen M. Wagman
 	 
	 	 	Name:  	Stephen M. Wagman 	 
	 	 	Title:  	Executive Vice President 	 
	 
	 	INTEGRAL POWER & TELECOMMUNICATIONS CORPORATION, LTD.

 	 
	 	By:  	/s/ Stephen M. Wagman
 	 
	 	 	Name:  	Stephen M. Wagman 	 
	 	 	Title:  	Executive Vice President 	 
	 
	 	MASTEC NORTH AMERICA AC, LLC

 	 
	 	By:  	/s/ Stephen M. Wagman
 	 
	 	 	Name:  	Stephen M. Wagman 	 
	 	 	Title:  	Executive Vice President 	 
	 

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]